Impact in focus

CEPI supports more than 150 active R&D and manufacturing projects in nearly 50 countries around the world, building critical capabilities for the 100 Days Mission. Find out how CEPI is advancing scientific innovations that could transform vaccine development and pandemic preparedness.
Each of CEPI’s scientific projects is designed to embed speed, scale and access into new vaccine development, and behind each innovation is a team of scientists striving to better protect the world against epidemic and pandemic threats. Read our innovations for impact stories to meet them and find out about their work.
Brazil is building the capability to develop and produce its own mRNA vaccines, strengthening pandemic preparedness at home and across Latin America.
Japanese scientists are exploring whether an AI-designed "Nanoball" mRNA vaccine could protect against a deadly tick-borne virus and also help the world respond faster to the next Disease X.
In the Democratic Republic of Congo, mothers and babies are taking part in crucial trials to find out how vaccines against Mpox can be used safely to protect some of those at greatest risk.
CEPI’s Research Preparedness Programme is strengthening clinical trial infrastructure, systems and skills at frontline sites across West Africa.
A first-of-its kind CEPI‑supported Phase 3 trial of Moderna’s mRNA‑based H5N1 vaccine candidate aims to help the world prepare for a potential bird flu pandemic.
Discover how CEPI and partners are preparing the world to face down a future Nipah virus outbreak.
H5N1 doesn’t have the mutations needed to spread easily between people. Yet. If it does, the global response time will be critical. Find out how new AI techniques are boosting the speed and success of vaccine development.
Former head of COVAX, Aurélia Nguyen, shares her reflections on the achievements of this pioneering vaccine-sharing scheme.
Read the story behind CEPI’s pioneering R&D response to the COVID-19 pandemic and how these lessons are contributing to the 100 Days Mission to accelerate the development of future pandemic-busting vaccines.
CEPI’s outbreak response experts reflect on how Rwanda was able to implement an emergency trial of a Marburg vaccine just 10 days after the outbreak was declared.
Find out how Institut Pasteur de Dakar and CEPI are partnering to help scale-up Africa’s capability to produce vaccines, both for routine immunisation and in preparation against a future pandemic pathogen.
Read how researchers are working to reduce the risks posed by Rift Valley fever in Africa and beyond.
Dr Kumblytee Johnson shares her frontline experiences of Lassa fever and how, with CEPI’s support, she and a team of researchers are working on the world’s most advanced Lassa vaccine candidate.
Scientific innovation is the life blood of CEPI. With more than 400 R&D partners, innovative projects are at the heart of our coalition. From rapid and unprecedented outbreak responses to future-proofing viral defences, CEPI’s research partners are breaking new ground in epidemic and pandemic preparedness. Learn more about the teams behind CEPI’s pandemic-busting innovations.
Prof. Hypolite Muhindo-Mavoko talks about the challenges and rewards that come with conducting vaccine trials for deadly viruses in the isolated city of Boende
Joining the CEPI-run Centralized Laboratory Network starts a new chapter in the almost century-long history of the illustrious Uganda Virus Research Institute.
"We push ourselves forward in our work because we feel the weight of the Lassa problem and we know the burden of the disease."
To help humanity get ahead, we need vaccines that provide broad protection against new variants of COVID-19 as well as future coronavirus threats.
See how CEPI’s work is accelerating vaccine development and strengthening pandemic preparedness.
©2026 CEPI. All rights reserved